Abstract
De novo drug development is an extremely time-consuming process with a high risk of failure and tremendous resource requirements. For these reasons, a drug-repurposing strategy has gained significant attention as a cost-effective alternative strategy. Drug repurposing can rapidly repurpose FDA-approved drugs to other indications than the approved indications. Until now, drug repurposing is serendipitous, such as repurposing Sildenafil for erectile dysfunction, and sometimes requires extensive manual reviews of related literature, clinical trials, and relevant clinical data. With an ever-growing amount of literature and information, an automatic method is much needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
